on Steroidal Anti-Inflammatory Drugs and the antiplatelet effects of acetylsalicylic acid.
- Conditions
- Acetylsalicylic acidNSAIDsAntiplateletAcetylsalicylzuurNSAIDsAntitrombotisch
- Registration Number
- NL-OMON27645
- Lead Sponsor
- H.E. Vonkeman, M.D., Ph.D., rheumatologist, epidemiologist: is the performer of the trial
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Healthy volunteers.
Exclusion Criteria
1. Use of medicins of any kind (also alternative medicins) except for oral contraceptives;
2. Allergy to acetylsalicylic acid and / or NSAID’s;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To measure the pharmacodynamic interaction between naproxen + acetylsalicylic acid as compared to the placebo + acetylsalicylic interaction. Also the pharmacodynamic interaction between acetylsalicylic acid and other in The Netherlands often used NSAID's will be examined: ibuprofen, meloxicam and etorixocib (also compared to placebo + acetylsalicylic acid).<br /><br>The main study parameter is the difference in closure time (sec) as a measure of platelet aggregation. Closure time is measured by the Platelet Function Analyzer-100 (PFA-100). This apparatus measures the time needed for the blood to aggregate. <br>The difference calculated, is closure time of the addition of an NSAID to acetylsalicylic acid, versus closure time of acetylsalicylic acid and placebo within one subject.
- Secondary Outcome Measures
Name Time Method